Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Drug-related genotyping kit and typing method for thiopurine drug

A genotyping and kit technology, applied in the direction of biochemical equipment and methods, microbial measurement/inspection, etc., to avoid adverse drug reactions, improve clinical treatment effect, and increase concentration

Inactive Publication Date: 2019-03-19
SUZHOU INST OF BIOMEDICAL ENG & TECH CHINESE ACADEMY OF SCI
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There are obvious individual differences in the clinical drug efficacy and adverse drug reactions of thiopurine drugs. About 67% of the users are effective, about 15% of the users are ineffective, and about 17% of the users will have very serious or even life-threatening diseases. Adverse drug reactions, such as bone marrow suppression, liver toxicity, pancreatitis, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drug-related genotyping kit and typing method for thiopurine drug
  • Drug-related genotyping kit and typing method for thiopurine drug
  • Drug-related genotyping kit and typing method for thiopurine drug

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0069] This embodiment provides a nucleic acid amplification reagent, including the following components:

[0070] Taq enzyme, 300mg / mL;

[0071] dNTPs, 100g / L;

[0072] Tris-HCl, 1mL / L;

[0073] MgCl 2 , 20g / L;

[0074] KCl, 10g / L;

[0075] (NH 4 ) 2 SO 4 , 10g / L;

[0076] Nano silica, 50g / L;

[0077] Triton X-100, 2mL / L.

[0078] The preparation method of nano-silica comprises the following steps:

[0079] (1) The solution I and the solution II are stirred and preheated to a reaction temperature of 110° C. on a heating stirrer, mixed and added to a three-necked flask of a thermal constant temperature heating magnetic stirrer. Wherein, solution I is obtained by mixing ammonia water: water: ethanol in a volume ratio of 20: 1: 79, and ammonia water is an aqueous solution with an ammonia content of 25% by weight; solution II is mixed by ethyl orthosilicate and ethanol in a volume ratio of 1: 4 get;

[0080] (2) stirring for 5 minutes, the mixed solution of solution ...

experiment example 2

[0085] This embodiment provides a nucleic acid amplification reagent, including the following components:

[0086] Taq enzyme, 500mg / mL;

[0087] dNTPs, 50g / L;

[0088] Tris-HCl, 0.5mL / L;

[0089] MgCl 2 , 10g / L;

[0090] KCl, 5g / L;

[0091] (NH 4 ) 2 SO 4 , 5g / L;

[0092] Nano silica, 100g / L;

[0093]Triton X-100, 5mL / L.

[0094] The preparation method of nano-silica comprises the following steps:

[0095] (1) The solution I and the solution II are stirred and preheated to a reaction temperature of 100° C. on a heating stirrer, mixed and added to a three-necked flask of a thermal constant temperature heating magnetic stirrer. Wherein, solution I is obtained by mixing ammonia water: water: ethanol in a volume ratio of 5: 1: 44, and ammonia water is an aqueous solution with an ammonia content of 26 wt %; solution II is mixed by ethyl orthosilicate and ethanol in a volume ratio of 3: 17 get;

[0096] (2) stirring for 5 minutes, the mixed solution of solution I and s...

experiment example 3

[0099] This embodiment provides a nucleic acid amplification reagent, including the following components:

[0100] Taq enzyme, 100mg / mL;

[0101] dNTPs, 200g / L;

[0102] Tris-HCl, 2mL / L;

[0103] MgCl 2 , 40g / L;

[0104] KCl, 20g / L;

[0105] (NH 4 ) 2 SO 4 , 40g / L;

[0106] Nano silica, 20g / L;

[0107] Triton X-100, 1mL / L.

[0108] The preparation method of nano-silica comprises the following steps:

[0109] (1) The solution I and the solution II are stirred and preheated to a reaction temperature of 120° C. on a heating stirrer, mixed and added to a three-necked flask of a thermal constant temperature heating magnetic stirrer. Wherein, solution I is obtained by mixing ammonia water: water: ethanol in a volume ratio of 60: 1: 139, and ammonia water is an aqueous solution with an ammonia content of 27wt%; solution II is mixed by ethyl orthosilicate and ethanol in a volume ratio of 3:7 get;

[0110] (2) stirring for 5 minutes, the mixed solution of solution I and so...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Particle sizeaaaaaaaaaa
Login to View More

Abstract

The invention belongs to the technical field of gene amplification detection, and particularly relates to a drug-related genotyping kit and a typing method for a thiopurine drug. Use of nano-silica ingene amplification detection is initiatively found, and gene amplification reaction efficiency and reaction specificity can be remarkably improved, so that the nano-silica is applied to drug-relatedgenotyping detection of the thiopurine drug to solve the problems that drug-related genotyping for the thiopurine drug is poor in specificity and low in detection speed, and a large number of samplescannot be rapidly detected in a high-specificity manner in the prior art.

Description

technical field [0001] The invention belongs to the technical field of gene amplification detection, and in particular relates to a drug-related genotyping kit and a genotyping method for thiopurine drugs. Background technique [0002] The research results of the World Health Organization show that the problem of drug safety is one of the most important causes of death in hospitalized patients, and even ranks fifth among all causes of death. The results of pharmacogenetics and genomics studies have shown that single nucleotide polymorphisms (SNPs) of drug-metabolizing enzymes can determine the activities of drug-metabolizing enzymes, thereby affecting the clinical efficacy and toxicity of drugs. When different individuals with different SNPs take the same drug, there are also individual differences in the clinical efficacy and toxicity of the drug. Therefore, how to analyze and identify the SNP differences of drug metabolizing enzymes among individuals, and use this differe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6883C12Q1/6886C12Q1/6858
CPCC12Q1/6858C12Q1/6883C12Q1/6886C12Q2600/106C12Q2600/156C12Q2531/113C12Q2527/125C12Q2563/107
Inventor 周连群李金泽张芷齐李传宇姚佳张威郭振
Owner SUZHOU INST OF BIOMEDICAL ENG & TECH CHINESE ACADEMY OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com